The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer’s disease.

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...

Firstly, the authors provided a detailed explanation of the experimental methods and procedures. This study recruited 30 healthy subjects (15 males and 15 females), aged between 20 to 50 years, with ...

Glaucoma patients show slower visual response times, indicating impaired visual signal processing rather than motor or attention deficits. The study involved glaucoma patients and healthy controls, ...